	Page 1		
1	UNITED STATES PATENT AND TRADEMARK OFFICE		
	BEFORE THE PATENT TRIAL AND APPEAL BOARD		
2			
	U.S. Patent No. 6,331,415		
3			
	Inter Partes Review No: IPR2016-00710		
4			
5	MYLAN PHARMACEUTICALS INC.		
_	AND MERCK SHARP & DOHME		
6	CORP.,		
7	Petitioners,		
8	VS.		
9	GENENTECH, INC. AND CITY OF		
10	HOPE,		
10	Patent Owners.		
11	ratent Owners.		
12			
13			
	BILZIN SUMBERG PRICE & AXELROD,		
14	LLP		
	1450 BRICKELL AVENUE		
15	SUITE 3200		
	MIAMI, FL 33131		
16	Friday, March 3, 2017		
	9:00 a.m 1:40 p.m.		
17			
18			
19	DEPOSITION OF REINER GENTZ, PH.D		
20			
21	Taken on behalf of the Petitioners before		
22	Elizabeth Cordoba, RMR, CRR, FPR, Notary Public in		
23	and for the State of Florida at Large, pursuant to		
24	Petitioners' Notice of Taking Deposition in the above		
25	cause.		

Veritext Legal Solutions

www.veritext.com 888-391-3376



		Page 2	
1	APPEARANCES:		
2	ATTORNEYS FOR PETITIONERS MYLAN:		
3	ERIC R. HUNT, ESQ.		
	NEIL MCLAUGHLIN, PH.D.		
4	RAKOCZY MOLINO MAZZOCHI SIWIK, LLP		
	6 WEST HUBBARD STREET		
5	CHICAGO IL 60634		
	312-222-6314		
6	Ehunt@rmmslegal.com		
	Nmclaughlin@rmmslegal.com		
7			
8	ATTORNEYS FOR PETITIONERS MERCK:		
9	MATTHEW A. TRAUPMAN, ESQ.		
	QUINN EMANUEL		
10	51 MADISON AVENUE		
	22ND FLOOR		
11	NEW YORK NY 10010		
	212-849-7322		
12	Matthewtraupman@quinnemanuel.com		
13			
1 /	ATTORNEYS FOR PATENT OWNERS:		
14			
15	ADAM R. BRAUSA, ESQ. DURIE TANGRI		
Τ Ͻ	217 LEIDESDORFF STREET		
16	SAN FRANCISCO CA 94111		
10	415-362-6666		
17	Abrausa@durietangri.com		
18			
19			
20			
21			
22			
23			
24			
25			



		Page 3
1	INDEX	
2	WITNESS	PAGE
3	REINER GENTZ, PH.D	
	Direct Examination by Mr. McLaughlin	5
4	Cross-Examination by Mr. Brausa	152
5		
6	EXHIBITS	
7	NUMBER DESCRIPTION	PAGE
8	Exhibit 1079, 1982 Stueber Article,	77
9	Exhibit 1080, 1984 Stueber Article,	82
10	Exhibit 1081, US Patent Number 6,541,224,	143
11		
12	PREVIOUSLY MARKED EXHIBITS	
13	Exhibit 2021,	6
14	Exhibit 1005,	51
15	Exhibit 2079,	57
16	Exhibit 2078,	75
17	Exhibit 1002,	118
18	Exhibit 2005,	133
19	Exhibit 2070,	136
20	Exhibit 2071,	138
21	Exhibit 2067,	141
22		
23		
24		
25		



1	Thereupon

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

having been first duly sworn or affirmed and responded,

REINER GENTZ, PH.D,

"Yes," was examined and testified as follows:

MR. MCLAUGHLIN: Good morning, Dr. Gentz. I just want to start by saying this is a deposition being taken in Inter-Partes Review Proceeding IPR2016-00710. It is an IPR between Mylan and Merck and Genentech and City of Hope.

Do you understand that you are here to provide testimony?

THE WITNESS: I understand.

MR. MCLAUGHLIN: In this IPR?

THE WITNESS: Yes.

MR. MCLAUGHLIN: We will do counsel appearances now. I am Neil McLaughlin from the law firm Rakoczy Molino, on behalf of the Mylan defendant/petitioner.

MR. HUNT: Eric Hunt, also from Rakoczy Molino Mazzochi Siwik, on behalf of the Mylan petitioner.

MR. TRAUPMAN: Matt Traupman from Quinn Emanuel, representing petitioner Merck.

MR. BRAUSA: Adam Brausa, from Durie Tangri, on behalf of respondents Genentech, City of Hope, as well as the witness Dr. Gentz.

THE WITNESS: And I am Reiner Gentz, from Gentz



1	Biotechnology	Consultants
---	---------------	-------------

### DIRECT EXAMINATION

#### BY MR. MCLAUGHLIN:

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

25

Q. So you were deposed last year in another IPR. So you probably heard these same instructions, but I will just go over them briefly again. Let's try not to talk over each other. I will ask questions. If you could wait until my question is finished and then provide your answer, that way we will have a clear record and the court reporter will have a clear time today.

We will take breaks from time to time.

- A. Okay.
- Q. Usually about every hour. But any time you need a break, feel free to let us know. I just ask that you not take a break while a question is pending.
  - A. I know.
- Q. Your counsel will object from time to time.

  You are still obligated to answer the question, unless of course it is a privilege objection and then you have been instructed not to answer.

Do you understand these --

- A. I understand.
- Q. -- instructions? Okay.

So since the deposition last year, have you been deposed in any other matter?



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

